Sarepta Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Sarepta Therapeutics has a total shareholder equity of $1.1B and total debt of $1.2B, which brings its debt-to-equity ratio to 113.9%. Its total assets and total liabilities are $3.4B and $2.3B respectively. Sarepta Therapeutics's EBIT is $38.0M making its interest coverage ratio -2.7. It has cash and short-term investments of $1.5B.
Key information
113.9%
Debt to equity ratio
US$1.23b
Debt
| Interest coverage ratio | -2.7x |
| Cash | US$1.46b |
| Equity | US$1.08b |
| Total liabilities | US$2.35b |
| Total assets | US$3.42b |
Recent financial health updates
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15
Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Recent updates
Sarepta Therapeutics Muscles Up In DMD Race
Sep 19Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
Jul 24Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%
Jul 05Sarepta Therapeutics: Navigating Elevidys Upside Potential
Jun 17Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear
May 08Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
May 05Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Apr 11Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 10There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues
Dec 20Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
Aug 08Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder
Jul 29Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?
May 09Sarepta: The DMD Leader
Apr 26Financial Position Analysis
Short Term Liabilities: SRPT's short term assets ($2.7B) exceed its short term liabilities ($688.5M).
Long Term Liabilities: SRPT's short term assets ($2.7B) exceed its long term liabilities ($1.7B).
Debt to Equity History and Analysis
Debt Level: SRPT has more cash than its total debt.
Reducing Debt: SRPT's debt to equity ratio has increased from 39.2% to 113.9% over the past 5 years.
Debt Coverage: SRPT's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: SRPT earns more interest than it pays, so coverage of interest payments is not a concern.